Medicine Recommendations

Treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.

Pain associated with osteoarthritis

Constipation in children

Bowel obstruction - colic associated with bowel obstruction AND GI secretions associated with bowel obstruction

Respiratory tract secretions in the last days of life

Treatment of: hypersalivation in adults and children (non-Parkinson’s disease)

For Hypersalivation/ Sialorrhoea in Adults with Parkinson’s Disease

Rheumatoid arthritis (LSCMMG pathway)

Prevention of recurrence of ulcerative colitis following surgery

Second line biologic for moderate to severe active ulcerative colitis ONLY where patients have had adalimumab 1st line .

Second line in psoriatic arthritis (PsA) following discontinuation of first anti-TNF due to an adverse event or primary or secondary inefficacy.

Psoriatic arthritis (NICE TA220)

First line biologic for moderate to severe active ulcerative colitis after the failure of conventional therapy (NICE TA329) and LSCMMG Recommendation

NICE TA329  Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy

Ankylosing spondylitis (NICE TA383)

NICE TA383 - TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis

Non-radiographic axial spondyloarthritis (NICE TA497)

NICE TA497 - Golimumab for treating non-radiographic axial spondyloarthritis

Treatment of Asthma. Treatment of COPD.

ADHD in children and adolescents aged 6 to 17 years for whom stimulants are not suitable, not tolerated or have been shown to be ineffective

Guselkumab for treating moderate to severe plaque psoriasis (NICE TA521)

For treating active psoriatic arthritis after inadequate response to DMARDs.

NICE TA711 - Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs

Treating active psoriatic arthritis after inadequate response to DMARDs - NICE TA815

NICE TA815 - Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs

Administration in patients with respiratory conditions